Small Molecule Inhibition of MERTK Is Efficacious in Non–Small Cell Lung Cancer Models Independent of Driver Oncogene Status

Treatment of non–small cell lung cancer (NSCLC) has been transformed by targeted therapies directed against molecular aberrations specifically activated within an individual patient's tumor. However, such therapies are currently only available against a small number of such aberrations, and new targets and therapeutics are needed. Our laboratory has previously identified the MERTK receptor tyrosine kinase (RTK) as a potential drug target in multiple cancer types, including NSCLC. We have recently developed UNC2025—the first-in-class small molecule inhibitor targeting MERTK with pharmacokinetic properties sufficient for clinical translation. Here, we utilize this compound to further validate the important emerging biologic functions of MERTK in lung cancer pathogenesis, to establish that MERTK can be effectively targeted by a clinically translatable agent, and to demonstrate that inhibition of MERTK is a valid treatment strategy in a wide variety of NSCLC lines independent of their driver oncogene status, including in lines with an EGFR mutation, a KRAS/NRAS mutation, an RTK fusion, or another or unknown driver oncogene. Biochemically, we report the selectivity of UNC2025 for MERTK, and its inhibition of oncogenic downstream signaling. Functionally, we demonstrate that UNC2025 induces apoptosis of MERTK-dependent NSCLC cell lines, while decreasing colony formation in vitro and tumor xenograft growth in vivo in murine models. These findings provide further evidence for the importance of MERTK in NSCLC, and demonstrate that MERTK inhibition by UNC2025 is a feasible, clinically relevant treatment strategy in a wide variety of NSCLC subtypes, which warrants further investigation in clinical trials. Mol Cancer Ther; 14(9); 2014–22. ©2015 AACR.

[1]  L. Stewart,et al.  Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 , 2015, Molecular Cancer Therapeutics.

[2]  S. Frye,et al.  Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia , 2015, Oncotarget.

[3]  K. Davies,et al.  The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer , 2014, Nature Reviews Cancer.

[4]  R. Salgia,et al.  AXL mediates resistance to cetuximab therapy. , 2014, Cancer research.

[5]  D. Newton,et al.  UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor , 2014, Journal of medicinal chemistry.

[6]  K. Davies,et al.  Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer , 2014, Oncotarget.

[7]  H. Gogas,et al.  Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. , 2014, Cancer letters.

[8]  G. Dy,et al.  Targeted therapies in development for non-small cell lung cancer , 2013, Journal of carcinogenesis.

[9]  S. Frye,et al.  Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. , 2013, Journal of medicinal chemistry.

[10]  M. Coumar,et al.  Treat cancers by targeting survivin: just a dream or future reality? , 2013, Cancer treatment reviews.

[11]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. D’Incecco,et al.  Targeted therapy for NSCLC with driver mutations , 2013, Expert opinion on biological therapy.

[13]  S. Frye,et al.  UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia In Vitro and In Vivo , 2013, Molecular Cancer Therapeutics.

[14]  S. Frye,et al.  UNC1062, a new and potent Mer inhibitor. , 2013, European journal of medicinal chemistry.

[15]  Michael Thomas,et al.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.

[16]  C. Miller,et al.  MERTK receptor tyrosine kinase is a therapeutic target in melanoma. , 2013, The Journal of clinical investigation.

[17]  H. Earp,et al.  Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia , 2013, Oncogene.

[18]  D. DeRyckere,et al.  Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia , 2013, Blood Cancer Journal.

[19]  A. Pierce,et al.  Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology , 2012, Oncogene.

[20]  W. Franklin,et al.  Mer or Axl Receptor Tyrosine Kinase Inhibition Promotes Apoptosis, Blocks Growth, and Enhances Chemosensitivity of Human Non-Small Cell Lung Cancer , 2012, Oncogene.

[21]  Jae Cheol Lee,et al.  Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer , 2012, Nature Genetics.

[22]  S. Frye,et al.  Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. , 2012, ACS medicinal chemistry letters.

[23]  H. Earp,et al.  Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors , 2010, Expert opinion on therapeutic targets.

[24]  A. Gemma,et al.  F1000 highlights , 2010 .

[25]  A. Thorburn,et al.  Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity , 2010, Molecular Cancer Therapeutics.

[26]  N. Joyce,et al.  Protein tyrosine phosphatase, PTP1B, expression and activity in rat corneal endothelial cells , 2007, Molecular vision.

[27]  L. Meltesen,et al.  Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase , 2006, Oncogene.

[28]  H. Snodgrass,et al.  Ectopic Expression of the Proto-oncogene Mer in Pediatric T-Cell Acute Lymphoblastic Leukemia , 2006, Clinical Cancer Research.

[29]  Y. Chu,et al.  Expression of axl in lung adenocarcinoma and correlation with tumor progression. , 2005, Neoplasia.

[30]  Renato Martins,et al.  Erlotinib in previously treated non-small-cell lung cancer. , 2005, The New England journal of medicine.

[31]  H. Kung,et al.  Signal Pathways in Up-regulation of Chemokines by Tyrosine Kinase MER/NYK in Prostate Cancer Cells , 2004, Cancer Research.

[32]  H. Serve,et al.  Expression and function of Flt3/flk2 in human tumor cell lines. , 1999, International journal of oncology.

[33]  H. Earp,et al.  Molecular Pathways Molecular Pathways : MERTK Signaling in Cancer , 2013 .

[34]  Kristen M. Jacobsen,et al.  LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia , 2013 .

[35]  H. Snodgrass,et al.  Cloning and Mrna Expression Analysis of a Novel Human Protooncogene, C-merr , 2022 .